2022
Pembrolizumab vs placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early triple-negative breast cancer (TNBC): Phase 3 KEYNOTE-522 study
Kümmel S, Cortés J, Dent R, Pusztai L, McArthur H, Bergh J, Denkert C, Park Y, Hui R, Harbeck N, Takahashi M, Untch M, Fasching P, Cardoso F, Ding Y, Tryfonidis K, Aktan G, Karantza V, O’Shaughnessy J, Schmid P. Pembrolizumab vs placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early triple-negative breast cancer (TNBC): Phase 3 KEYNOTE-522 study. European Journal Of Surgical Oncology 2022, 48: e30-e31. DOI: 10.1016/j.ejso.2021.12.430.Peer-Reviewed Original Research
2021
Treatment scheduling effects on the evolution of drug resistance in heterogeneous cancer cell populations
Patwardhan GA, Marczyk M, Wali VB, Stern DF, Pusztai L, Hatzis C. Treatment scheduling effects on the evolution of drug resistance in heterogeneous cancer cell populations. Npj Breast Cancer 2021, 7: 60. PMID: 34040000, PMCID: PMC8154902, DOI: 10.1038/s41523-021-00270-4.Peer-Reviewed Original ResearchHeterogeneous cancer cell populationsCancer cell populationsTriple-negative breast cancerSingle-cell RNA sequencingCell populationsFitness advantageRNA sequencingMDA-MB-231 TNBC cellsDrug resistanceMechanisms of resistanceVitro screening assaysClonal dynamicsTNBC cellsScreening assaysResistant clonesPatterns of resistanceConcomitant treatmentTherapy combinationsBreast cancerClinical studiesTreatment doseTreatment scheduleBarcodesSequencingTreatment
2016
Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach
Safonov A, Wang S, Gross CP, Agarwal D, Bianchini G, Pusztai L, Hatzis C. Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach. Breast Cancer Research And Treatment 2016, 155: 223-234. PMID: 26749360, PMCID: PMC5990969, DOI: 10.1007/s10549-016-3677-3.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsCost-effectiveness analysisPredictive biomarkersBiomarker-guided treatmentIncremental cost-effectiveness ratioHealth-related qualityTreatment costsCost-effectiveness ratioClinical outcomesClinical efficacyPrognostic biomarkerTraditional cost-effectiveness analysisBiomarker useLife yearsBiomarker valuesBiomarker prevalenceClinical literatureBiomarkersTreatmentState transition modelDecision analytic approachMedical utilityDecision analytic toolsCrizotinibHER2
2006
Hétérogénéité moléculaire des cancers du sein: quelles implications pour la sélection des patientes en vue d’une chimiothérapie adjuvante?
André F, Pusztai L. Hétérogénéité moléculaire des cancers du sein: quelles implications pour la sélection des patientes en vue d’une chimiothérapie adjuvante? Oncologie 2006, 8: 235-242. DOI: 10.1007/s10269-006-0382-6.Peer-Reviewed Original Research
2004
Improving patient care through molecular diagnostics
Perez EA, Pusztai L, van De Vijver M. Improving patient care through molecular diagnostics. Seminars In Oncology 2004, 31: 14-20. PMID: 15490370, DOI: 10.1053/j.seminoncol.2004.07.017.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBreast NeoplasmsDihydrouracil Dehydrogenase (NADP)Gene Expression ProfilingGenes, erbB-2HumansImmunohistochemistryIn Situ Hybridization, FluorescenceMolecular Diagnostic TechniquesOligonucleotide Array Sequence AnalysisProteomicsReceptor, ErbB-2Reverse Transcriptase Polymerase Chain ReactionThymidine PhosphorylaseConceptsLymph node statusPresence of metastasesSpecific tumor subtypesSingle tumor markerAdverse eventsMolecular diagnosticsNode statusSpecific therapyBreast cancerEstrogen receptorHistologic appearanceTumor gradingTumor markersTumor subtypesPatient careDiagnostic testsInitial evaluationParticular molecular defectsPatientsTherapyCancerParticular treatmentTreatmentSimultaneous assessmentDiagnostic techniques